查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085309

心臟生物標記市場：按生物標記類型、臨床背景、應用和最終用戶分類－2026-2032年全球市場預測

Cardiac Biomarker Market by Biomarker Type, Clinical Setting, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，心臟生物標記市場將成長至 270.9 億美元，複合年成長率為 9.43%。

主要市場統計數據
基準年 2025 144.1億美元
預計年份：2026年 156.5億美元
預測年份 2032 270.9億美元
複合年成長率 (%) 9.43%

心臟生物標記市場概覽

心臟生物標記市場的發展主要受臨床對快速、準確檢測、風險分層和監測心血管疾病的需求所驅動。世界衛生組織（WHO）指出，心血管疾病仍是全球首要死因，每年約造成1,790萬人死亡。因此，市場對心肌肌鈣蛋白、腦鈉肽（BNP）、N末端腦鈉肽前體（NT-proBNP）、肌酸激酶同工酶（CK-MB）、肌紅蛋白、D-二聚體以及發炎、缺血和纖維化等新型標記物的需求仍然旺盛。

正在重塑心臟生物標記診斷的變革性變化

心臟生物標記領域正從以單一標記、以醫院為中心的檢測模式，轉向更快、更靈敏、更注重協作的診斷模式。高敏肌鈣蛋白檢測方案縮短了「確診」和「排除」急性冠狀動脈症候群所需的時間，並且當與檢驗的臨床路徑結合使用時，能夠幫助臨床醫生在確保患者安全的同時，減少不必要的住院治療。

人工智慧對心臟生物標記的累積影響

人工智慧 (AI) 對心臟生物標記檢測的累積影響正在整體。它並非取代檢驗的檢測方法，而是作為一種輔助手段，提升結果解讀、最佳化工作流程並增強風險預測。人工智慧驅動的臨床決策支援系統能夠整合肌鈣蛋白動力學、利鈉肽濃度、心電圖觀察、症狀、患者背景、腎功能、用藥史和既往心血管事件等信息，從而提高分診的一致性。

心臟生物標記市場的關鍵區域洞察

由於人口老化、糖尿病和高血壓盛行率上升、醫院網路不斷擴展，以及中國、印度、日本、澳洲和韓國等國先進診斷技術的普及，亞太地區對心臟生物標記的需求尤為迫切。日本和澳洲已擁有成熟的高靈敏度檢測和基於指南的急診醫學體系，而印度和東南亞部分地區則為經濟實惠的即時心臟生物標記平台提供了巨大的發展機遇，這些平台能夠支持都市區、農村和二級醫療機構的早期分診。

關於引入心臟生物標記的關鍵群體特定見解

東協地區在心臟生物標記市場蘊藏著多元化的機會。新加坡和馬來西亞的高品質診斷技術正在不斷進步，而印尼、越南、菲律賓和泰國則透過醫院擴建、急診醫學發展和公共衛生投資，擴大了醫療服務的覆蓋範圍。目前最大的需求是價格合理、操作簡便的診斷方法，這些方法既可在集中式檢查室運行，也可在分散式醫療環境中運行，同時還要確保品管、操作人員培訓和網路連接的穩定性。

主要國家對心臟生物標記的需求趨勢

美國憑藉其先進的醫院網路、規範的檢測方法、急診科診療流程以及積極採用高敏肌鈣蛋白，在心臟生物標記創新領域處於領先地位。加拿大強調實證心血管護理和各省公平的醫療服務，而墨西哥則透過投資公立和私立醫院來提升診斷能力。巴西是拉丁美洲最大的市場，這得益於其高心血管疾病負擔、不斷擴展的私人檢測網路以及不斷完善的循環系統醫療保健服務。

為行業領導者提供的實用建議

產業領導者應優先考慮經臨床檢驗的高靈敏度診斷測試、擴充性的即時檢測平台以及能夠縮短診斷時間的整合式數位化工作流程。產品策略應同時滿足高階醫院檢查室和注重成本的分散式醫療機構的需求，提供一系列測試，以支持急性冠狀動脈症候群、心臟衰竭、血栓症、發炎和手術全期風險評估。

調查方法

本執行摘要基於結構化的調查方法，該方法結合了二手資料研究、一手檢驗整合和資料三角驗證。資訊來源包括公共衛生機構、同儕審查的循環系統文獻、權威專業協會的臨床實踐指南、法律規範、診斷行業資訊披露、醫院採購趨勢、檢查室認證要求以及國家心血管疾病統計數據。

結論

隨著醫療系統致力於更早診斷、快速急診分流和更好地管理心血管疾病，心臟生物標記的重要性日益凸顯。高敏肌鈣蛋白、利鈉肽、床邊檢測、多重檢測平台和人工智慧輔助評估正在重新定義臨床醫生評估心肌損傷、心臟衰竭、血栓症和心血管風險的方式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：心臟生物標記市場：依生物標記類型分類

  • BNP 和 NT-proBNP
  • 肌酸激酶（CK）MB
  • 肌紅蛋白
  • 肌鈣蛋白

第8章：心臟生物標記市場：依臨床背景分類

  • 臨床試驗
  • 即時檢測

第9章：心臟生物標記市場：依應用領域分類

  • 診斷
    • 急性冠狀動脈症候群
    • 鬱血性心臟衰竭
    • 心肌梗塞
  • 前景
  • 風險評估

第10章：心臟生物標記市場：依最終用戶分類

  • 診斷檢查室
  • 醫院和診所
  • 研究機構

第11章：心臟生物標記市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：心臟生物標記市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 心臟生物標記市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abbott Laboratories
  • Abcam plc
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • bioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • Epitope Diagnostics Inc.
  • F. Hoffmann-La Roche AG
  • Fujirebio Diagnostics Inc.
  • Guangzhou Wondfo Biotech Co., Ltd.
  • Hologic Inc.
  • Johnson & Johnson Services, Inc.
  • Life Diagnostics, Inc.
  • LSI Medience Corporation
  • Meridian Bioscience, Inc.
  • Myriad RBM Inc.
  • PerkinElmer, Inc.
  • Quest Diagnostics Incorporated
  • QuidelOrtho Corporation
  • Randox Laboratories Limited
  • Sekisui Medical Co., Ltd.
  • Siemens Healthineers AG
  • Singulex, Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Tosoh Corporation
  • Trinity Biotech plc
Product Code: MRR-433AB1DC288D

The Cardiac Biomarker Market is projected to grow by USD 27.09 billion at a CAGR of 9.43% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.41 billion
Estimated Year [2026] USD 15.65 billion
Forecast Year [2032] USD 27.09 billion
CAGR (%) 9.43%

Cardiac Biomarker Market Executive Overview

The cardiac biomarker market is anchored by the clinical need to detect, risk-stratify, and monitor cardiovascular disease with speed and accuracy. Cardiovascular disease remains the leading cause of death globally, accounting for an estimated 17.9 million deaths each year according to the World Health Organization, which keeps demand high for cardiac troponin, BNP, NT-proBNP, CK-MB, myoglobin, D-dimer, and emerging inflammatory, ischemia, and fibrosis markers.

High-sensitivity cardiac troponin assays have become central to emergency department evaluation of suspected myocardial infarction, while natriuretic peptide testing supports heart failure diagnosis, prognosis, and therapy monitoring in line with major cardiology guideline recommendations. Growth is also supported by point-of-care cardiac biomarker testing, laboratory automation, integrated clinical decision support, and broader adoption of evidence-based chest pain pathways across hospitals, diagnostic laboratories, and ambulatory care settings.

Transformative Shifts Reshaping Cardiac Biomarker Diagnostics

The cardiac biomarker landscape is shifting from single-marker, hospital-centered testing toward faster, higher-sensitivity, and more connected diagnostic models. High-sensitivity troponin protocols have shortened rule-in and rule-out timelines for acute coronary syndrome, helping clinicians reduce unnecessary admissions while protecting patient safety when used with validated clinical pathways.

A second shift is the movement of testing closer to the patient. Point-of-care platforms are increasingly relevant for emergency care, rural health, ambulances, urgent care, and low-resource settings where central laboratory turnaround can delay treatment. At the same time, multiplex assays and proteomics are expanding the biomarker pipeline beyond injury markers toward inflammation, fibrosis, thrombosis, and cardiometabolic risk.

Regulatory and quality expectations are also rising. The European Union In Vitro Diagnostic Regulation, FDA oversight, and national laboratory accreditation requirements are pushing manufacturers to strengthen analytical validation, clinical evidence, cybersecurity, interoperability, traceability, and post-market surveillance.

Cumulative Impact of Artificial Intelligence on Cardiac Biomarkers

Artificial intelligence is becoming a cumulative force across cardiac biomarker testing, not as a replacement for validated assays but as an enhancer of interpretation, workflow, and risk prediction. AI-enabled clinical decision support can combine troponin kinetics, natriuretic peptide levels, electrocardiogram findings, symptoms, demographics, renal function, medication history, and prior cardiovascular events to improve triage consistency.

In laboratories, machine learning is being applied to quality control, anomaly detection, instrument utilization, test-demand planning, and turnaround-time management. In hospitals, AI can help identify patients at risk of heart failure decompensation, perioperative myocardial injury, or adverse cardiac events by integrating biomarker trends with electronic health record data.

The strongest opportunities depend on transparent validation. Algorithms must be assessed across sex, age, ethnicity, renal impairment, comorbidity, and care-setting differences to reduce bias and maintain clinician trust. Leaders that pair regulated diagnostics with explainable AI, robust data governance, privacy-by-design architecture, and prospective outcome studies will be best positioned.

Key Regional Insights Across the Cardiac Biomarker Market

Asia-Pacific is a high-priority region for cardiac biomarker demand due to aging populations, rising diabetes and hypertension prevalence, expanding hospital networks, and increasing access to advanced diagnostics in China, India, Japan, Australia, and South Korea. Japan and Australia show mature adoption of high-sensitivity testing and guideline-led emergency care, while India and parts of Southeast Asia offer strong opportunities for affordable point-of-care cardiac biomarker platforms that can support early triage across urban, rural, and tier-two healthcare settings.

North America remains a technologically advanced region supported by established emergency medicine pathways, regulated diagnostics, broad laboratory infrastructure, and strong clinical guideline adoption. Latin America, led by Brazil and Mexico, is expanding access through private hospital investment, reference laboratory development, and public-sector modernization, although reimbursement variability, workforce distribution, and geographic inequality continue to affect testing penetration and turnaround time consistency.

Europe benefits from strong cardiology societies, standardized care pathways, and widespread use of high-sensitivity troponin, while IVDR compliance is reshaping supplier strategies around evidence generation and post-market performance. The Middle East is investing in tertiary hospitals, emergency care infrastructure, and preventive cardiology, particularly across the Gulf. Africa presents a long-term access opportunity where portable, robust, and cost-effective testing can address delayed diagnosis, limited laboratory capacity, and cardiovascular disease underdiagnosis in decentralized care environments.

Key Group Insights for Cardiac Biomarker Adoption

ASEAN represents a diverse cardiac biomarker opportunity, with Singapore and Malaysia advancing high-quality diagnostics while Indonesia, Vietnam, the Philippines, and Thailand scale access through hospital expansion, emergency care development, and public health investment. Demand is strongest for affordable, easy-to-use assays that can operate across centralized laboratories and decentralized care environments while maintaining quality control, operator training, and connectivity.

The GCC is prioritizing advanced cardiac care through hospital modernization, specialist centers, digital health programs, and national health transformation initiatives, supporting adoption of high-sensitivity assays and connected diagnostic platforms. The European Union is shaped by harmonized regulatory oversight under IVDR, strong guideline adherence, and growing emphasis on clinical evidence, traceability, laboratory accreditation, and post-market performance.

BRICS countries combine large patient populations with rising cardiovascular risk, making them critical for volume-led access, local manufacturing, and cost-sensitive innovation. G7 markets lead in premium assay adoption, automation, AI integration, quality assurance, and reimbursement sophistication. NATO members, while not a healthcare bloc, increasingly emphasize supply-chain resilience, cybersecurity, emergency preparedness, and continuity of critical diagnostic infrastructure.

Key Country Insights Shaping Cardiac Biomarker Demand

The United States leads in cardiac biomarker innovation through advanced hospital networks, regulated assays, emergency department protocols, and strong adoption of high-sensitivity troponin. Canada emphasizes evidence-based cardiovascular care and equitable access across provinces, while Mexico is expanding diagnostic capacity through public and private hospital investment. Brazil is Latin America's largest opportunity, supported by a substantial cardiovascular disease burden, growing private laboratory networks, and expanding cardiology services.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from strong cardiology guidance, mature laboratory systems, and structured acute coronary syndrome pathways, with Germany and France particularly influential in diagnostic procurement, laboratory standardization, and clinical validation. Russia maintains demand through large hospital systems and high cardiovascular disease burden, although procurement dynamics, regional infrastructure, and technology access can vary significantly.

China is rapidly scaling cardiac biomarker testing through hospital modernization, broader insurance coverage, and domestic diagnostic manufacturing. India offers major growth potential for affordable point-of-care and laboratory testing due to high cardiovascular risk, diabetes prevalence, and uneven access between metropolitan and rural regions. Japan, Australia, and South Korea are mature, quality-focused markets with strong adoption of high-sensitivity assays, digital health infrastructure, advanced cardiovascular care pathways, and strong emphasis on analytical performance.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated high-sensitivity assays, scalable point-of-care platforms, and integrated digital workflows that reduce time to diagnosis. Product strategies should address both premium hospital laboratories and cost-sensitive decentralized settings, with assay menus that support acute coronary syndrome, heart failure, thrombosis, inflammation, and perioperative risk assessment.

Manufacturers should invest in regulatory readiness, especially IVDR clinical evidence, quality-system expectations, cybersecurity, interoperability, and post-market surveillance. Partnerships with hospitals, emergency medicine networks, reference laboratories, and academic cardiology groups can generate real-world evidence demonstrating reduced turnaround time, improved triage, fewer avoidable admissions, and better patient outcomes.

Commercial leaders should localize pricing, training, service models, connectivity, and supply chains by region. AI-enabled offerings should be explainable, prospectively validated, integrated into clinician workflows, and governed by clear data privacy, bias monitoring, and clinical accountability frameworks rather than positioned as standalone tools.

Research Methodology

This executive summary is developed from a structured research methodology combining secondary research, primary insight synthesis, and data triangulation. Sources considered include public health agencies, peer-reviewed cardiology literature, clinical practice guidelines from recognized professional societies, regulatory frameworks, diagnostic industry disclosures, hospital procurement trends, laboratory accreditation requirements, and national cardiovascular disease statistics.

The analysis emphasizes verified indicators such as disease burden, clinical guideline adoption, assay validation standards, regulatory requirements, care-delivery infrastructure, reimbursement environment, and regional access patterns. Qualitative insights are cross-checked against multiple credible sources to avoid unsupported market claims. AI-related conclusions are framed around documented applications in clinical decision support, laboratory workflow optimization, risk prediction, quality control, and governance requirements rather than speculative adoption assumptions.

Conclusion

Cardiac biomarkers are becoming more important as health systems seek earlier diagnosis, faster emergency triage, and better management of cardiovascular disease. High-sensitivity troponin, natriuretic peptides, point-of-care testing, multiplex platforms, and AI-enabled interpretation are redefining how clinicians evaluate myocardial injury, heart failure, thrombosis, and cardiovascular risk.

The market outlook is strongest for organizations that combine analytical accuracy, clinical evidence, workflow integration, regulatory readiness, and regional affordability. Companies that can meet evolving quality standards while supporting equitable access across hospitals, laboratories, emergency care, ambulatory care, and decentralized settings will shape the next phase of cardiac biomarker diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cardiac Biomarker Market, by Biomarker Type

  • 7.1. BNP & NT-proBNP
  • 7.2. Creatine Kinase (CK) MB
  • 7.3. Myoglobin
  • 7.4. Troponins

8. Cardiac Biomarker Market, by Clinical Setting

  • 8.1. Laboratory Testing
  • 8.2. Point Of Care Testing

9. Cardiac Biomarker Market, by Application

  • 9.1. Diagnosis
    • 9.1.1. Acute Coronary Syndrome
    • 9.1.2. Congestive Heart Failure
    • 9.1.3. Myocardial Infarction
  • 9.2. Prognosis
  • 9.3. Risk Assessment

10. Cardiac Biomarker Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Hospitals & Clinics
  • 10.3. Research Institutes

11. Cardiac Biomarker Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Cardiac Biomarker Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Cardiac Biomarker Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbott Laboratories
  • 15.2. Abcam plc
  • 15.3. Becton, Dickinson and Company
  • 15.4. Bio-Rad Laboratories Inc.
  • 15.5. bioMerieux SA
  • 15.6. Danaher Corporation
  • 15.7. DiaSorin S.p.A.
  • 15.8. Epitope Diagnostics Inc.
  • 15.9. F. Hoffmann-La Roche AG
  • 15.10. Fujirebio Diagnostics Inc.
  • 15.11. Guangzhou Wondfo Biotech Co., Ltd.
  • 15.12. Hologic Inc.
  • 15.13. Johnson & Johnson Services, Inc.
  • 15.14. Life Diagnostics, Inc.
  • 15.15. LSI Medience Corporation
  • 15.16. Meridian Bioscience, Inc.
  • 15.17. Myriad RBM Inc.
  • 15.18. PerkinElmer, Inc.
  • 15.19. Quest Diagnostics Incorporated
  • 15.20. QuidelOrtho Corporation
  • 15.21. Randox Laboratories Limited
  • 15.22. Sekisui Medical Co., Ltd.
  • 15.23. Siemens Healthineers AG
  • 15.24. Singulex, Inc.
  • 15.25. Sysmex Corporation
  • 15.26. Thermo Fisher Scientific Inc.
  • 15.27. Tosoh Corporation
  • 15.28. Trinity Biotech plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC BIOMARKER MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CARDIAC BIOMARKER MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CARDIAC BIOMARKER MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CARDIAC BIOMARKER MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CARDIAC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BNP & NT-PROBNP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BNP & NT-PROBNP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BNP & NT-PROBNP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CREATINE KINASE (CK) MB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CREATINE KINASE (CK) MB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CREATINE KINASE (CK) MB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MYOGLOBIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MYOGLOBIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MYOGLOBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TROPONINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TROPONINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TROPONINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LABORATORY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LABORATORY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LABORATORY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MYOCARDIAL INFARCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MYOCARDIAL INFARCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MYOCARDIAL INFARCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PROGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RISK ASSESSMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RISK ASSESSMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RISK ASSESSMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. ASEAN CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GCC CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 96. GCC CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. GCC CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 98. GCC CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. GCC CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 100. GCC CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. BRICS CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 110. BRICS CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. G7 CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 114. G7 CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. G7 CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 116. G7 CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. G7 CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 118. G7 CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. NATO CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. NATO CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NATO CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 122. NATO CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. NATO CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 124. NATO CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 129. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. CANADA CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. CANADA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. CANADA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 135. CANADA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. CANADA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 137. CANADA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. MEXICO CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 141. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 143. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRAZIL CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 147. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 149. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GERMANY CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 159. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 161. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. FRANCE CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 165. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 167. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. RUSSIA CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. RUSSIA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. RUSSIA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 171. RUSSIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. RUSSIA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 173. RUSSIA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. ITALY CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. ITALY CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ITALY CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 177. ITALY CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. ITALY CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 179. ITALY CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. SPAIN CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. SPAIN CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. SPAIN CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 183. SPAIN CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. SPAIN CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 185. SPAIN CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. INDIA CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. INDIA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. INDIA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 195. INDIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. INDIA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 197. INDIA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. JAPAN CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. JAPAN CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. JAPAN CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 201. JAPAN CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. JAPAN CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 203. JAPAN CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 207. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 209. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 213. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 215. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)